Clinical trial
Effect of Lithium and Divalproex in Alzheimer's Disease
NCT00088387 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00088387 |
|---|---|
| Title | Effect of Lithium and Divalproex in Alzheimer's Disease |
| Official title | Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Divalproex, Lithium |
| Enrollment | 35 |
| Start date | Jul 1, 2004 |
| Completion | Mar 1, 2005 |
| First posted | Jul 26, 2004 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: